WO2009103150A4 - Method for treating migraine headaches - Google Patents

Method for treating migraine headaches Download PDF

Info

Publication number
WO2009103150A4
WO2009103150A4 PCT/CA2009/000182 CA2009000182W WO2009103150A4 WO 2009103150 A4 WO2009103150 A4 WO 2009103150A4 CA 2009000182 W CA2009000182 W CA 2009000182W WO 2009103150 A4 WO2009103150 A4 WO 2009103150A4
Authority
WO
WIPO (PCT)
Prior art keywords
migraine
blocking agent
beta adrenergic
adrenergic blocking
solution
Prior art date
Application number
PCT/CA2009/000182
Other languages
French (fr)
Other versions
WO2009103150A1 (en
Inventor
Kevin David Smith
Original Assignee
Kevin David Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kevin David Smith filed Critical Kevin David Smith
Publication of WO2009103150A1 publication Critical patent/WO2009103150A1/en
Publication of WO2009103150A4 publication Critical patent/WO2009103150A4/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A beta adrenergic blocking agent, preferably Timolol maleate, or ocularly compatible salts thereof, are delivered topically in the form of one or more eye drops during the interval beginning from the time and within the first 30 minutes thereafter when a patient first senses the onset, or potential onset, of a migraine headache.

Claims

AMENDED CLAIMS received by the International Bureau on 05 August 2009 (05.08.2009)
1. A method for treatment of a person anticipating suffering from a migraine headache comprising topical administration of a therapeutically effective amount of a pharmaceutically acceptable solution of a beta adrenergic blocking agent, or an ocularly compatible salt thereof, in the form of one or more eye drops delivered to one or both eyes within 30 minutes of the first indication of said migraine.
2. The method as in claim 1 wherein the beta adrenergic blocking agent is selected from the group consisting of betoxoloh. levobunolo^ carteololi metipranoloL. levobetaxolol, and timolol.
3. The method as in claim 1 or 2 wherein the solution is administered to both eyes.
4. The method as in any one of claims 1 to 3, wherein the eye drops are administered repeatedly thereafter in a similar manner every half hour for up to two hours in cases where the migraine persists.
5. The method as in any one of claims 1 to 4 comprising administration of an aqueous pharmaceutical solution of Timolol maleate, or ocularly compatible salts thereof, at a concentration of from a 0.25% to 0.5%.
6. The method as in claim 5 wherein the pharmaceutical solution is a 0.5% aqueous solution.
7. Use of a therapeutically effective amount of a beta adrenergic blocking agent or an ocularly compatible salt thereof for treatment of a migraine, wherein said beta adrenergic blocking agent or ocularly compatible salt thereof is for ophthalmic administration within 30 minutes of a first indication of said migraine.
8. The use as in claim 7 wherein the beta adrenergic blocking agent is selected from the group consisting of betoxolol; levobunolol; carteolol; metipranolol; levobetaxolol; and timolol.
9. Use of a beta adrenergic blocking agent or an ocularly compatible salt thereof in the manufacture of an ophthalmic solution for treatment of a migraine, wherein said solution is for ophthalmic administration within 30 minutes of a first indication of said migraine,
10. The use as in claim 9 wherein the beta adrenergic blocking agent is selected from the group consisting of betoxolol; levobunolol; carteolol; metipranolol; levobetaxolol; and timolol.
10 Statement under Article 19 (I) The claims have been amended as follows:
Claim 2 has been amended to recite beta blocking agents in Markush format. Support for this amendment is found at paragraph [0013]. A similar amendment has been made to claims 8 and 10. Claims 3, 5 and 7 have been amended for better clarity.
No new matter has been entered by way of the above amendments.
This statement is accompanied by a letter as required under Section 205(b).
11
PCT/CA2009/000182 2008-02-20 2009-02-20 Method for treating migraine headaches WO2009103150A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3013208P 2008-02-20 2008-02-20
US61/030,132 2008-02-20

Publications (2)

Publication Number Publication Date
WO2009103150A1 WO2009103150A1 (en) 2009-08-27
WO2009103150A4 true WO2009103150A4 (en) 2009-10-15

Family

ID=40985019

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2009/000182 WO2009103150A1 (en) 2008-02-20 2009-02-20 Method for treating migraine headaches

Country Status (1)

Country Link
WO (1) WO2009103150A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502089A (en) * 2014-01-10 2017-01-19 マニスティー パートナーズ エルエルシーＭａｎｉｓｔｅｅ Ｐａｒｔｎｅｒｓ Ｌｌｃ Migraine treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242949A (en) * 1992-03-13 1993-09-07 Rugby-Darby Group Companies, Inc. Treating classic migraine
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6685951B2 (en) * 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing

Also Published As

Publication number Publication date
WO2009103150A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
US20120295914A1 (en) Combination of adrenergic receptor agonist alpha-1 or alpha-2, preferably brimonidine with fillers, preferably hyaluronic acid
EP2598119B1 (en) Preservative free brimonidine and timolol solutions
WO2009077736A4 (en) A medicament comprising a parasympathetic agonist and a sympathetic antagonist or a sympathetic agonist
AU784017B2 (en) Solutions containing epinastine
CA2440764A1 (en) Combination of brimonidine and timolol for topical ophthalmic use
JP2005523316A5 (en)
CA2502437A1 (en) Method and composition containing latanoprost for treating ocular hypertension and glaucoma
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
CN103747786A (en) Fixed dose combination of bimatoprost and brimonidine
WO2003082081A3 (en) Use of rom production and release inhibitors to treat and prevent intraocular damage
JP2021102626A5 (en)
EP2726105A1 (en) A new stable anesthetic composition for reducing skin reactions
CN1231214C (en) 5HT2 agonists for controlling IOP and treating glaucoma
CN102665730A (en) Ophthalmic formulation and method of manufacture thereof
EP1283043B1 (en) Ophthalmic solution
CA2468664A1 (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
WO2009103150A4 (en) Method for treating migraine headaches
CA2454544A1 (en) Optic nerve protecting agents containing .alpha.1 receptor blocker as active ingredient
US10975121B2 (en) Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
JP2005239622A (en) Therapeutic agent for corneal disorder
CN105188700A (en) Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes
EP1148883B1 (en) Use of tricyclic antidepressants for treatment of headache
WO2003068166A3 (en) Treatment of ophthalmic disorders using urea and urea derivatives
WO2001030328A3 (en) Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions
JP2005289814A (en) Medicine for myopia correction surgery

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09713472

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09713472

Country of ref document: EP

Kind code of ref document: A1